IL287280A - Compounds and methods for the treatment of ocular disorders - Google Patents

Compounds and methods for the treatment of ocular disorders

Info

Publication number
IL287280A
IL287280A IL287280A IL28728021A IL287280A IL 287280 A IL287280 A IL 287280A IL 287280 A IL287280 A IL 287280A IL 28728021 A IL28728021 A IL 28728021A IL 287280 A IL287280 A IL 287280A
Authority
IL
Israel
Prior art keywords
compounds
treatment
methods
ocular disorders
ocular
Prior art date
Application number
IL287280A
Other languages
English (en)
Hebrew (he)
Original Assignee
Azura Ophthalmics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azura Ophthalmics Ltd filed Critical Azura Ophthalmics Ltd
Publication of IL287280A publication Critical patent/IL287280A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL287280A 2019-04-18 2021-10-14 Compounds and methods for the treatment of ocular disorders IL287280A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962835975P 2019-04-18 2019-04-18
US202062966482P 2020-01-27 2020-01-27
PCT/IB2020/000312 WO2020212760A2 (en) 2019-04-18 2020-04-16 Compounds and methods for the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
IL287280A true IL287280A (en) 2021-12-01

Family

ID=72837068

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287280A IL287280A (en) 2019-04-18 2021-10-14 Compounds and methods for the treatment of ocular disorders

Country Status (9)

Country Link
US (2) US11643429B2 (cg-RX-API-DMAC10.html)
EP (1) EP3955937A4 (cg-RX-API-DMAC10.html)
JP (2) JP7904691B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210154214A (cg-RX-API-DMAC10.html)
CN (1) CN114007625A (cg-RX-API-DMAC10.html)
AU (1) AU2020259997B2 (cg-RX-API-DMAC10.html)
CA (1) CA3136369A1 (cg-RX-API-DMAC10.html)
IL (1) IL287280A (cg-RX-API-DMAC10.html)
WO (1) WO2020212760A2 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020212755A1 (en) 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
AU2020259997B2 (en) 2019-04-18 2025-08-07 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
CA3196145A1 (en) * 2020-10-21 2022-04-28 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
CN116940570A (zh) * 2020-10-21 2023-10-24 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法
WO2023067387A2 (en) * 2021-10-20 2023-04-27 Azura Ophthalmics Ltd. Compounds and methods for the treatment of dermal and ocular disorders
TW202421700A (zh) 2022-07-28 2024-06-01 日商住友化學股份有限公司 偏光膜的製造方法及製造裝置
WO2024101918A1 (ko) * 2022-11-11 2024-05-16 주식회사 메디치바이오 리포-하이드록삼산 유도체 및 이의 약학적 용도
US20260109705A1 (en) * 2022-12-20 2026-04-23 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
WO2025012700A2 (en) * 2023-07-07 2025-01-16 Azura Ophthalmics Ltd. Compositions and methods for the treatment of autoimmune disorders

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
KR930702369A (ko) * 1990-10-15 1993-09-08 우에노 아키라 에리쓰로마이신 또는 그의 유도체의 2'위치 수식 화합물
WO1995018604A1 (en) * 1994-01-11 1995-07-13 Ciba-Geigy Ag Topical treatment of ocular photophobia
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
EP1101769A3 (en) * 1999-11-18 2001-10-24 Pfizer Products Inc. Nitrogen containing erythromycin derivatives
CA2445306C (en) * 2001-04-27 2008-02-12 Pfizer Products Inc. Process for preparing 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
FR2832637B1 (fr) * 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
EP1483277A4 (en) * 2002-02-15 2007-10-03 Merckle Gmbh CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF
GB0310962D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
GB0310980D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
GB0310984D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
CN1837225A (zh) * 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
GB0609373D0 (en) * 2006-05-11 2006-06-21 Glaxo Group Ltd Macrolones
PE20090879A1 (es) * 2007-07-30 2009-07-25 Glaxosmithkline Zagreb DERIVADOS 9-DESOXO-9a-METIL-9a-AZA-9a-HOMOERITROMICINA A COMO AGENTES ANTIMALARICOS
JP2012516305A (ja) * 2009-01-30 2012-07-19 グラクソ グループ リミテッド 好中球優位の炎症性疾患の治療のための9−デオキソ−9a−メチル−9a−アザ−9a−ホモエリスロマイシンa誘導体
WO2011100769A2 (en) * 2010-02-15 2011-08-18 Synovo Gmbh Kinase modulators for the treatment of cancer
WO2013003731A2 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
EP2831083A4 (en) * 2012-03-27 2016-03-09 Michael W Burnet INFLAMMATORY MAKROLIDE
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
CA3020713A1 (en) 2016-04-19 2017-10-26 Azura Ophthalmics Ltd. Compositions for the treatment of hyperkeratosis disorders
US11420995B2 (en) * 2017-03-03 2022-08-23 Synovo Gmbh Anti-infective and anti-inflammatory compounds
CA3057569A1 (en) 2017-03-29 2018-10-04 Azura Ophthalmics Ltd. Agents for increasing meibomian gland lipid secretion
WO2018215638A1 (en) * 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin
AU2020259997B2 (en) 2019-04-18 2025-08-07 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Also Published As

Publication number Publication date
CN114007625A (zh) 2022-02-01
WO2020212760A3 (en) 2021-02-25
CA3136369A1 (en) 2020-10-22
WO2020212760A2 (en) 2020-10-22
EP3955937A4 (en) 2023-01-18
JP2022529315A (ja) 2022-06-21
US20230348517A1 (en) 2023-11-02
US20210230205A1 (en) 2021-07-29
AU2020259997A1 (en) 2021-11-25
JP2026102607A (ja) 2026-06-23
JP7904691B2 (ja) 2026-08-13
AU2020259997B2 (en) 2025-08-07
KR20210154214A (ko) 2021-12-20
US11643429B2 (en) 2023-05-09
EP3955937A2 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
IL288214A (en) Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders
IL286636A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS
IL278178A (en) Use of pilocarpine hydrochloride to treat eye disorder
IL287264A (en) Compounds and methods for the treatment of ocular disorders
IL267818A (en) Methods for treating neurological disorders
ZA202002066B (en) Compositions and methods for the treatment of eye disorders
IL279634A (en) Preparations and methods for the treatment and prevention of neurological disorders
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
SG11202100092QA (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS
EP3661502A4 (en) COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL CONDITIONS AND THEIR USES
IL269400A (en) Medicines and preparations for the treatment of eye disorders
PT3603621T (pt) Lipossomas para o tratamento de doenças oculares
EP4010347A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN AND ADDICTION DISORDERS
EP3644966A4 (en) TREATMENT AND DIAGNOSIS OF EYE SURFACE DISORDERS
IL289221A (en) Compounds for the treatment of vision disorders
EP4232458A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES
SG11202012473UA (en) Ophthalmic compositions and methods for the treatment of eye disorders
IL288234A (en) Compounds for the treatment of neuromuscular disorders
IL317599A (en) Device for treating eye disorders
IL280588A (en) Ophthalmic compositions and methods for treating eye problems and skin diseases
GB2603379B (en) Avocatin B for the treatment of diseases and conditions
HK40074660A (en) Methods for the treatment of apoc3-related diseases and disorders
HK40084516A (en) Compounds and methods for the treatment of eye disorders
AU2020901856A0 (en) Compounds and Methods for the Treatment of Eye Disorders
AU2020901858A0 (en) Compounds and Methods for the Treatment of Eye Disorders